Your browser doesn't support javascript.
loading
Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
Seferovic, Petar M; Polovina, Marija; Bauersachs, Johann; Arad, Michael; Ben Gal, Tuvia; Lund, Lars H; Felix, Stephan B; Arbustini, Eloisa; Caforio, Alida L P; Farmakis, Dimitrios; Filippatos, Gerasimos S; Gialafos, Elias; Kanjuh, Vladimir; Krljanac, Gordana; Limongelli, Giuseppe; Linhart, Ales; Lyon, Alexander R; Maksimovic, Ruzica; Milicic, Davor; Milinkovic, Ivan; Noutsias, Michel; Oto, Ali; Oto, Öztekin; Pavlovic, Sinisa U; Piepoli, Massimo F; Ristic, Arsen D; Rosano, Giuseppe M C; Seggewiss, Hubert; Asanin, Milika; Seferovic, Jelena P; Ruschitzka, Frank; Celutkiene, Jelena; Jaarsma, Tiny; Mueller, Christian; Moura, Brenda; Hill, Loreena; Volterrani, Maurizio; Lopatin, Yuri; Metra, Marco; Backs, Johannes; Mullens, Wilfried; Chioncel, Ovidiu; de Boer, Rudolf A; Anker, Stefan; Rapezzi, Claudio; Coats, Andrew J S; Tschöpe, Carsten.
Afiliación
  • Seferovic PM; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Polovina M; Serbian Academy of Sciences and Arts, Belgrade, Serbia.
  • Bauersachs J; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Arad M; Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia.
  • Ben Gal T; Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany.
  • Lund LH; Cardiomyopathy Clinic and Heart Failure Institute, Leviev Heart Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Felix SB; Department of Cardiology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Arbustini E; Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
  • Caforio ALP; Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
  • Farmakis D; Centre for Inherited Cardiovascular Diseases, IRCCS Foundation, University Hospital Policlinico San Matteo, Pavia, Italy.
  • Filippatos GS; Division of Cardiology, Department of Cardiological, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
  • Gialafos E; University of Cyprus Medical School, Nicosia, Cyprus; Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece.
  • Kanjuh V; University of Cyprus Medical School, Nicosia, Cyprus; Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece.
  • Krljanac G; Second Department of Cardiology, Heart Failure and Preventive Cardiology Section, Henry Dunant Hospital, Athens, Greece.
  • Limongelli G; Serbian Academy of Sciences and Arts, Belgrade, Serbia.
  • Linhart A; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Lyon AR; Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia.
  • Maksimovic R; Department of Cardiothoracic Sciences, Università della Campania 'Luigi VanvitellI', Monaldi Hospital, AORN Colli, Centro di Ricerca Cardiovascolare, Ospedale Monaldi, AORN Colli, Naples, Italy, and UCL Institute of Cardiovascular Science, London, UK.
  • Milicic D; Second Department of Medicine, Department of Cardiovascular Medicine, General University Hospital, Charles University in Prague, Prague, Czech Republic.
  • Milinkovic I; National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, London, UK.
  • Noutsias M; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Oto A; Centre for Radiology and Magnetic Resonance Imaging, Clinical Centre of Serbia, Belgrade, Serbia.
  • Oto Ö; Department of Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.
  • Pavlovic SU; Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia.
  • Piepoli MF; Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Halle, Germany.
  • Ristic AD; Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Rosano GMC; Department of Cardiovascular Surgery, Dokuz Eylül University Faculty of Medicine, Izmir, Turkey.
  • Seggewiss H; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Asanin M; Pacemaker Center, Clinical Center of Serbia, Belgrade, Serbia.
  • Seferovic JP; Heart Failure Unit, Cardiology, G. da Saliceto Hospital, Piacenza, Italy.
  • Ruschitzka F; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Celutkiene J; Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia.
  • Jaarsma T; Department of Medical Sciences, IRCCS San Raffaele, Rome, Italy, and Cardiology Clinical Academic Group, St George's Hospitals NHS Trust University of London, London, UK.
  • Mueller C; Medizinische Klinik, Kardiologie & Internistische Intensivmedizin, Klinikum Würzburg-Mitte, Würzburg, Germany.
  • Moura B; University of Belgrade Faculty of Medicine, Belgrade, Serbia.
  • Hill L; Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia.
  • Volterrani M; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Lopatin Y; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Metra M; Department of Cardiology, University Heart Center, Zürich, Switzerland.
  • Backs J; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Mullens W; State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
  • Chioncel O; Department of Social and Welfare Studies, Faculty of Health Science, Linköping University, Linköping, Sweden.
  • de Boer RA; Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Anker S; Cardiology Department, Centro Hospitalar São João, Porto, Portugal.
  • Rapezzi C; School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
  • Coats AJS; Department of Cardiology, IRCCS San Raffaele Pisana, Rome, Italy.
  • Tschöpe C; Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russia.
Eur J Heart Fail ; 21(5): 553-576, 2019 05.
Article en En | MEDLINE | ID: mdl-30989768
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiomiopatía Hipertrófica / Cardiomiopatía Restrictiva / Cardiomiopatía Dilatada / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Pregnancy Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiomiopatía Hipertrófica / Cardiomiopatía Restrictiva / Cardiomiopatía Dilatada / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Pregnancy Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido